CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapyRARITAN, N.J., July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (P ...

文章核心观点 - 收益型投资者可以在任何市场环境中找到大量机会 [1] - 股息股票是一种很好的方式,可以为投资组合增加现金流,并随时间推移帮助复合整体收益 [1] - 投资股息股票时,需要确保公司有强大的基本面和资产负债表,以支持和增长支付的股息 [2] 公司分析 Johnson & Johnson - 已连续62年每年支付并增加股息,是"股息之王"中的佼佼者 [4] - 股息收益率为3.4%,是标普500平均水平的两倍以上 [5] - 过去10年股息年均增长6%,派息率仅30% [5] - 股价表现相对较弱,主要受到与其滑石粉产品相关的诉讼和潜在负债的影响 [6] - 公司拥有260亿美元现金,可用于管理诉讼并维持对股东的承诺 [6] - 公司营收860亿美元,利润170亿美元,自由现金流240亿美元 [7] - 去年将消费品业务分拆,专注于更快增长的制药和医疗器械业务 [8] - 长期投资者可能会发现该公司是一个有吸引力的投资机会 [9] 可口可乐 - 已连续62年每年增加股息,股息收益率约3% [10] - 过去5年和10年的总回报分别为46%和108% [10] - 在美国市场占据46%的碳酸饮料市场份额 [11] - 过去12个月利润110亿美元,营收460亿美元,利润率23% [12] - 派息率74%,仍处于可控水平,过去10年股息年均增长5% [12] - 过去12个月经营现金流120亿美元,自由现金流110亿美元 [13] - 尽管受到汇率和宏观环境波动的影响,但其股息承诺和资产负债表实力仍彰显了这家公司的抗风险能力 [13] - 长期持有型投资者可能会对可口可乐感兴趣 [14]

First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+HELSINKI, June 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over p ...

Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company.Johnson & Johnson (JNJ -0.25%) is focusing on the next iteration of its business -- one that investors hope creates a lot more growth than in years past. The company spun off its consumer health business last year, and with just two main segments moving forward -- medical devices and innovative medicines -- J&J could be in a good position to accelerate its growth rate.But investors don't ap ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $147.19, denoting a -1.29% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.09%. Meanwhile, the Dow experienced a drop of 0.1%, and the technology-dominated Nasdaq saw an increase of 0.16%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 1.46% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.The ...

J&J is the textbook blue chip stock -- but it's not for everyone.Investing comes in many flavors, so there isn't a right or wrong approach: You should do what's best for you. That applies even to dividend investing. For some, dividend investing means maximizing immediate income, even if it requires sacrificing some growth and long-term upside; for others, it's the opposite.Healthcare juggernaut Johnson & Johnson (JNJ 0.25%) is a hallowed name in the dividend community, both for its brand recognition and for ...

blackred FOMO (fear of missing out) is hard to ignore when it comes to buying stocks in today's market, especially when influencers post headline-making comments about meme stocks like GameStop (GME) or when expensive stocks just keep going up, as in the case of Nvidia (NVDA), whose market cap just surpassed that of Microsoft (MSFT) to become the world's most valuable company. I'm not bothered, however, by not participating in the aforementioned stock rallies as I'm happy to layer into discounted divide ...

Johnson & Johnson (JNJ) announced that it has submitted a supplemental biologics license application (sBLA) seeking approval of its immunology drug, Tremfya, for a new indication — moderately to severely active Crohn’s disease (CD). This marks the second label expansion filing for Tremfya in three months, following the sBLA in active ulcerative colitis (UC) indication that was filed in March.Tremfya is currently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in sever ...

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programsTREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's diseaseGALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn's diseaseSPRING HOUSE, Pa., June 20, 2 ...

文章核心观点 - 强生公司宣布其生物制剂TREMFYA®在III期克罗恩病临床试验中达到了所有主要和次要终点指标 [1][2][3] - TREMFYA®在克罗恩病治疗中展现出良好的疗效和安全性,有望成为唯一一种能够提供皮下和静脉注射两种给药途径的IL-23抑制剂 [2][3] - 该结果将在即将召开的医学会议上公布,并将提交给监管机构 [4] 根据目录分别总结 TREMFYA®在克罗恩病中的临床试验 - GRAVITI是一项随机、双盲、安慰剂对照的III期临床试验,评估TREMFYA®皮下给药方案在中重度活动性克罗恩病患者中的疗效 [6] - GALAXI是一项II/III期临床试验项目,评估TREMFYA®在中重度活动性克罗恩病患者中的疗效和安全性,包括与STELARA®的对照研究 [7] 克罗恩病的概况 - 克罗恩病是一种慢性肠道炎症性疾病,目前尚无治愈方法 [8][9] - 该病影响了约300万美国人和400万欧洲人,症状包括腹痛、腹泻、体重下降等 [8][9] TREMFYA®的机制和适应症 - TREMFYA®是强生公司开发的首个完全人源化的双效单克隆抗体,通过抑制IL-23发挥治疗作用 [10] - TREMFYA®已获批用于治疗中重度斑块状银屑病和活动性银屑病性关节炎 [11]